Zymeworks Inc. · NASDAQ:ZYME
Zymeworks — AACR Annual Meeting 2026
16 slides from Zymeworks's conference presentation, Apr 20, 2026
Slide 1: Phase 1 first-in-human study of ZW191, an FRα-targeting ADC: Part 1 dose-escalation results
Phase 1 first-in-human multicenter open-label study of ZW191, a folate receptor α (FRα)–targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors: Part 1 dose-escalation results Patricia LoRusso,1 David Sommerhalder,2 Kosei Hasegawa,3 Kenichi Harano,4 David Shao Peng Tan,5 Nobo
Slide 2: Disclosure information
Disclosure information Dr. Patricia LoRusso I have the following relevant financial relationships to disclose: Participation on a Data Safety Monitoring Board or Advisory Board for AbbVie, Takeda, IQVIA, Glaxo-Smith Kline, Pfizer, QED Therapeutics, AstraZeneca, EMD Serono, Kyowa Kirin Pharmaceutical
Slide 3: ZW191 antibody-drug conjugate binds FRα, which is highly expressed in advanced solid tumors
ZW191 antibody-drug conjugate binds FRα, which is highly expressed in advanced solid tumors Folate receptor alpha (FRα) is a clinically validated therapeutic • FRα-targeting antibody target highly expressed in ovarian cancer (OC), endometrial • Novel TOPOIi payload (ZD06519) cancer (EC), and non–sma
Slide 4: ZWI-ZW191-101 study design
ZWI-ZW191-101 study design IN PROGRESS PART 1 PART 1: DOSE ESCALATION PART 2A: DOSE OPTIMIZATION PART 2B: DOSE EXPANSION KEY ELIGIBILITY CRITERIA Randomized 1:1: OC, EC, and NSCLC OC 6.4 mg/kg (n=30) EC n=20 NSCLC n=20 • ≥18 years old with recurrent: 9.6 mg/kg (n=30) ─ Platinum-resistant OC Intraven
Slide 5: Demographic and baseline characteristics
Demographic and baseline characteristics 1.6 mg/kg 3.2 mg/kg 4.8 mg/kg 6.4 mg/kg 8.0 mg/kg 9.6 mg/kg 11.2 mg/kg Total Overall population (n=3) (n=3) (n=6) (n=12) (n=12) (n=12) (n=3) (n=51) Female, n (%) 3 (100) 3 (100) 6 (100) 11 (92) 11 (92) 12 (100) 3 (100) 49 (96) Median age (range), years 62 (58
Slide 6: Prior systemic treatment
Prior systemic treatment 1.6 mg/kg 3.2 mg/kg 4.8 mg/kg 6.4 mg/kg 8.0 mg/kg 9.6 mg/kg 11.2 mg/kg Total Overall population (n=3) (n=3) (n=6) (n=12) (n=12) (n=12) (n=3) (n=51) Median prior lines of 2 (1-4) 3 (2-4) 3 (1-7) 4 (2-7) 3 (2-9) 5 (2-6) 5 (3-7) 3 (1-9) therapy (range) 1.6 mg/kg 3.2 mg/kg 4.8 m
Slide 7: Safety and tolerability of ZW191: TEAEs
Safety and tolerability of ZW191: TEAEs 1.6 mg/kg 3.2 mg/kg 4.8 mg/kg 6.4 mg/kg 8.0 mg/kg 9.6 mg/kg 11.2 mg/kg Total ZW191 TEAE, n (%) (n=3) (n=3) (n=6) (n=12) (n=12) (n=12) (n=3) (n=51) Any TEAE 2 (67) 3 (100) 6 (100) 12 (100) 12 (100) 12 (100) 3 (100) 50 (98) Grade ≥3 TEAE 2 (67) 2 (67) 4 (67) 4 (
Slide 8: Safety and tolerability of ZW191: TEAEs
Safety and tolerability of ZW191: TEAEs 1.6 mg/kg 3.2 mg/kg 4.8 mg/kg 6.4 mg/kg 8.0 mg/kg 9.6 mg/kg 11.2 mg/kg Total ZW191 TEAE, n (%) (n=3) (n=3) (n=6) (n=12) (n=12) (n=12) (n=3) (n=51) Any TEAE 2 (67) 3 (100) 6 (100) 12 (100) 12 (100) 12 (100) 3 (100) 50 (98) Grade ≥3 TEAE 2 (67) 2 (67) 4 (67) 4 (
Slide 9: TEAEs of any grade occurring in ≥20% of participants
TEAEs of any grade occurring in ≥20% of participants Across all dose levels (n=51) Any grade 100 Grade ≥3 90 80 Participants, % 70 60 50 40 30 20 10 0 ue ia ea ea a n ia ia e ia g ni itin io tit x em en em ti g rh us re pe pe at m op ar Py An Fa s Na tip ap ro Vo ne Di yt ns ut c ag d Ne Co bo e m a
Slide 10: TEAEs of any grade occurring in ≥20% of participants (cont.)
TEAEs of any grade occurring in ≥20% of participants (cont.) ZW191 6.4 mg/kg (n=12) ZW191 9.6 mg/kg (n=12) Nausea Any grade Grade 3 Fatigue Grade 4 Neutropenia Anemia Vomiting Constipation Hypomagnesemia Pyrexia Thrombocytopenia Decreased appetite Diarrhea -100 -80 -60 -40 -20 0 20 40 60 80 100 Part
Slide 11: Antitumor activity of ZW191: Ovarian cancer
Antitumor activity of ZW191 Ovarian cancer (n=34) 1.6 mg/kg FRα expression PS2+ score: 0%-24% 25%-74% 75%-100% Not evaluated 70 3.2 mg/kg 4.8 mg/kg 60 6.4 mg/kg 50 8.0 mg/kg 30 40 9.6 mg/kg Change from baseline in sum of diameters of target lesions (%) 11.2 mg/kg 20 30 Treatment ongoing Best change
Slide 12: Antitumor activity of ZW191: Endometrial cancer
Antitumor activity of ZW191 Endometrial cancer (n=10) FRα expression PS2+ score: 0%-24% 25%-74% 75%-100% 1.6 mg/kg 3.2 mg/kg 4.8 mg/kg 70 6.4 mg/kg 60 8.0 mg/kg 30 Change from baseline in sum of 9.6 mg/kg diameters of target lesions (%) 50 20 11.2 mg/kg 40 Treatment ongoing Best change from baseline
Slide 13: Duration of treatment and overall response of ZW191
Duration of treatment and overall response of ZW191 Ovarian and endometrial cancer (n=46) FRα expression PS2+ score: 0%-24% 25%-74% 75%-100% Not evaluated Total across OC and EC 6.4-9.6 mg/kg dose levels OC (n=35) mTTR, mo (range) 1.4 (1.2-4.2) 1.4 (1.2-4.2) 1.6 mg/kg 3.2 mg/kg 4.8 mg/kg mDOR, mo (9
Slide 14: Pharmacokinetics of ZW191
Pharmacokinetics of ZW191 Antibody-conjugated payload Free payload 1.6 mg/kg 3.2 mg/kg 10,000 100 4.8 mg/kg Ac-ZD06519 concentration 6.4 mg/kg ZD06519 concentration 8.0 mg/kg 9.6 mg/kg 1000 10 11.2 mg/kg (ng/mL) (ng/mL) 100 1 10 0.1 1 0.01 0 7 14 21 0 7 14 21 Days Days PK analysis (n=47): exposure g
Slide 15: Conclusions
Conclusions ZW191 demonstrated a broad therapeutic window and demonstrated competitive efficacy in both high and low FRα-expressing tumors, justifying further investigation, as monotherapy and/or in combination • ZW191 was well tolerated and safely administered up to 11.2 mg/kg • 6.4-9.6 mg/kg demon
Slide 16: Acknowledgments & Support
Acknowledgments & Support ZWI-ZW191-101 is ongoing at 27 sites across multiple regions, including North America, Europe, and the Asia-Pacific We sincerely thank all participants and their families. We thank all the investigators, clinical trial researchers, personnel, and staff who contributed Unite